 | Up a level |
Haddad, Robert; Guigay, Joel; Keilholz, Ulrich; Clement, Paul M; Fayette, Jérôme; de Souza Viana, Luciano; Rolland, Frédéric; Cupissol, Didier; Geoffrois, Lionnel; Kornek, Gabriela; Licitra, Lisa; Melichar, Bohuslav; Ribaldo Nicolau, Ulisses; Rauch, Daniel; Zanetta-Devauges, Sylvie; Cohen, Ezra E W; Machiels, Jean-Pascal; Tahara, Makoto; Vermorken, Jan; Geng, Yuan; ... (2019). Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial. Oral oncology, 97, pp. 82-91. Elsevier 10.1016/j.oraloncology.2019.08.004
Burtness, Barbara; Haddad, Robert; Dinis, José; Trigo, José; Yokota, Tomoya; de Souza Viana, Luciano; Romanov, Ilya; Vermorken, Jan; Bourhis, Jean; Tahara, Makoto; Martins Segalla, José Getulio; Psyrri, Amanda; Vasilevskaya, Irina; Nangia, Chaitali Singh; Chaves-Conde, Manuel; Kiyota, Naomi; Homma, Akihiro; Holeckova, Petra; Del Campo, Josep Maria; Asarawala, Nirav; ... (2019). Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial. JAMA oncology, 5(8), pp. 1170-1180. American Medical Association 10.1001/jamaoncol.2019.1146
